Drug Pricing & Access
Expert articles and analysis related to drug pricing & access.
AI Summary — Last 7 Days
Drug pricing activity this week centered on how federal payment models can translate lower net drug costs into accountable-care performance: KFF’s analysis of the Trump administration’s Medicaid GENEROUS Model cautions that savings will depend heavily on confidential model terms, baseline supplemental rebates, and state participation—meaning Medicaid ACOs and risk-bearing providers should not assume uniform pharmacy-cost relief across markets (KFF GENEROUS Model brief). In Medicare, biosimilar uptake is increasingly being framed as a VBC execution issue, with provider performance in value-based payment models tied to formulary strategy, prescribing behavior, and the ability to capture savings without disrupting access (AJMC on biosimilars and VBC). Together, the week’s developments point to a sharper operational tension for ACOs, health systems, and payers: drug-cost savings opportunities are expanding, but realizing them will require tighter alignment among pharmacy benefit design, clinician incentives, quality measures, and patient access safeguards.
Related Articles
A Look at the GENEROUS Model and Factors That Could Impact Medicaid Drug Costs
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the model’s overall impact on Medicaid drug costs, and illustrates how savings will depend on m...
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2025 - Office of Inspector General (.gov)
Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2025 Office of Inspector General (.gov)
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
From newsletter: This Week: There Are Many MAHAs This Week: There Are Many MAHAs Plus, the cost of health care is a more prominent focus for MAHA voters than issues like food and vaccine policy. ͏ ͏ ͏...
CMS to provide Medicare Part D beneficiaries with $50 monthly access to certain GLP-1 medications
CMS to provide Medicare Part D beneficiaries with $50 monthly access to certain GLP-1 medications American Hospital Association
Comments on biosimilar streamlining efforts and context on commercial barriers to competition
Comments on biosimilar streamlining efforts and context on commercial barriers to competition Brookings
MFN Drug Pricing Proposal Raises Questions Around Access, Innovation, and Commercial Coverage
Amgen, AbbVie say IRA negotiations impacted Q1 sales
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in their...
STAT+: Administration report on most favored nation drug pricing raises new details — and questions
Administration report on most-favored nation drug pricing raises new details — and questions.
Most Favored Nation Drug Pricing: Anchoring To A Moving Target
Most Favored Nation Drug Pricing: Anchoring To A Moving Target Health Affairs
Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy
Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy Health Affairs